拉莫三嗪治疗Lennox-Gastaut综合征的临床观察

Lamotrigine in the treatment of Lennox-Gastaut syndrome.

应用拉莫三嗪添加、开放性自身对照法观察Lennox-Gastaut综合征患者8例,观察时间为3～31个月。结果:应用LTG后,2例患者(25%)癫痫发作停止,4例患者(50%)癫痫发作减少大于75%,总有效率75%。LTG对Lennox-Gastaut综合征的各型癫痫发作均有较好效果,脑电图有改善的倾向。部分患者应用LTG治疗后生活质量有一定的改善。副作用少。治疗前后各项实验室检查未见有临床意义的异常改变。

8 patients with Lennox-Gastaut syndrome (L-GS) entered an open add-on study with Lamotrigine (LTG) to assess the efficacy and safety. The treatment period was 3 to 3] months. The results was that 2 patients with L-GS became seizure-free after 1 to 5 months of LTG treatment(25%), the seizure frequency was decreased >50% in ( patients (50%) compared with that in the per-LTG period, 75% of the patients with L-GS were LTG responders. LTG appeared to be effective over a broad range of different seizure types. An improved trend of EEG after LTG treatment seemed to be noted. Some patients's quality of life (QOL) were improved during the study. The adverse events reported rare. Laboratory parameters showed no consistent findings of clinical significance.